Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, and happy birthday to me! Today, we see the Senate Appropriations Committee look to increase NIH funding, despite the Trump administration’s request to slash it. Also, Trump makes drug pricing demands, and…
Today we talk about an advance in an experimental mRNA vaccine for HIV, dive deep on Vinay Prasad’s sudden FDA departure, and more. The need-to-know this morning Inside the undoing of Vinay Prasad at the FDA Vinay Prasad’s short-lived but polarizing run as head of the FDA’s biologics division ended just 84 days in, after his…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got another busy news day. My colleagues were working hard last night. Let’s get right into that. Vinay Prasad, top FDA official, exits under pressure Vinay Prasad, a top official at…
In a closely watched case, a U.S. federal court judge has temporarily blocked a first-in-the-nation law that would prohibit companies that own pharmacy benefit managers from also operating both retail and mail-order pharmacies in Arkansas. The state law is designed to eliminate concerns that the largest pharmacy benefit managers — which are controlled by CVS Health,…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. It’s a busy day for biotech news, let’s get right to it. The need-to-know this morning Merck, AstraZeneca, and Incyte reported earnings for the second quarter. Novo Nordisk lowered its sales and operating…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today, we talk about a JAMA study that outlines the downstream effects of the NIH cutting research costs, see one man survive a likely case of ALS thus far, perhaps thanks to an FUS-targeting drug,…